Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...

A major European clinical research event in oncology gives a boost to antibody–drug conjugates, treatments that work like a Trojan horse, delivering chemotherapy to the interior of malignant cells ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).

(Alliance News) - GSK PLC on Monday announced an agreement with Syndivia that grants GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate for metastatic ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.